トップページ > 研究業績 > 1999年以前
地域連携感染制御学講座
緑膿菌感染症研究会
第50回緑膿菌感染症研究会
第7回私立医科大学病院感染対策協議会
第22回マクロライド新作用研究会
研究室メンバー専用

お問い合わせ・連絡先

東邦大学 医学部
微生物・感染症学講座
(医学部 1号館 9階)

〒143-8540
東京都大田区大森西5-21-16
TEL 03-3762-4151

1999年以前

No. 著者名 演題名 掲載誌名 ページ
1 Hirakata Y, Tomono K, Tateda K, Matsumoto T, Furuya N, Shimoguchi K, Kaku M and Yamaguchi K Role of bacterial association with Kupffer cells in occurrence of endogenous systemic bacteremia Infect Immun 59 289-294 1991
2 Miyazaki S, Miyazaki Y, Tsuji A, Nishida M and Goto S In vitro and in vivo studies of ME1228, a new parenteral cephalosporin with potent activity against Pseudomonas aeruginosa Antimicrob Agents Chemother 35 1245-1246 1991
3 Miyazaki S, Miyazaki Y, Tsuji A, Nishida M and Yamaguchi K In vitro antibacterial activity of ME1207, a new oral cephalosporin Antimicrob Agents Chemother 35 1691-1694 1991
4 Hirakata Y, Kaku M, Tomono K, Tateda K, Furuya N, Matsumoto T, Araki R and Yamaguchi K Efficacy of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice Antimicrob Agents Chemother 36 1198-1203 1992
5 Goto S, Miyazaki S and Kaneko Y The in vitro activity of RP59500 against Gram-positive cocci J Antimicrob Chemother 30 25-28 1992
6 Imada T, Miyazaki S, Nishida M, Yamaguchi K and Goto S In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116 Antimicrob Agents Chemother 36 573-579 1992
7 Miyazaki S, Matsunaga T, Kobayashi I, Yamaguchi K and Goto S The other mediator for adherence of Haemophilus influenzae organisms without involvement of fimbriae Microbiol Immunol 36 205-212 1992
8 Hirakata Y, Kaku M, Mizukane R, Ishida K, Furuya N, Matsumoto T, Tateda K and Yamaguchi K Potential effects of erythromycin on host defense systems and virulence of Pseudomonas aeruginosa Antimicrob Agents Chemother 36 1922-1927 1992
9 Miyazaki S, Matsunaga T, Kawasaki K, Kobayashi I, Tada H, Yamaguchi K and Goto S Separate isolation of Clostridium difficile spores and vegetative cells from the feces of newborn infants Microbiol Immunol 36 131-138 1992
10 Furuya N, Hirakata Y, Tomono K, Matsumoto T, Tateda K, Kaku M and Yamaguchi K Mortality rates amongst mice with endogenous septicaemia caused by Pseudomonas aeruginosa isolates from various clinical sources J Med Microbiol 39 141-146 1993
11 Hirakata Y, Kaku M, Furuya N, Matsumoto T, Tateda K and Yamaguchi K Contribution of difference in blood clearance of bacteria to development of systemic bacteremia J Med Microbiol 38 337-344 1993
12 Miyazaki S, Ohno A, Kobayashi I, Uji T, Yamaguchi K and Goto S Cytotoxic effect of hemolytic culture supernatant from Enterococcus faecalis on mouse polymorphonuclear neutrophils and macrophages Microbiol Immunol 37 265-270 1993
13 Tateda K, Tomono K, Hirakata Y, Furuya N, Sugahara K, Saniel MC, Tupasi TE and Yamaguchi K Prevalence of antimicrobial resistance in Haemophilus influenzae and Streptococcus pneumoniae; Comparison of clinical isolates of Japan and the Philippines Trop Med 35 43-52 1993
14 Hirakata Y, Furuya N, Tateda K, Kaku M and Yamaguchi K In vivo production of exotoxin A and its role in endogenous Pseudomonas aeruginosa septicemia in mice Infect Immun 61 2468-2473 1993
15 Matsumoto T, Kaku M, Furuya N, Usui T, Kohno S, Tomono K, Tateda K, Hirakata Y and Yamaguchi K Amphotericin B-induced resistance to Pseudomonas aeruginosa infection in mice J Antibiot 46 777-784 1993
16 Tateda K, Hirakata Y, Furuya N, Ohno A and Yamaguchi K Effects of subMICs of erythromycin and other macrolide antibiotics on serum sensitivity of Pseudomonas aeruginosa Antimicrob Agents Chemother 37 675-680 1993
17 Toyosawa T, Miyazaki S, Tsuji A, Yamaguchi K and Goto S In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin Antimicrob Agents Chemother 37 60-66 1993
18 Fujii K, Tsuji A, Miyazaki S, Yamaguchi K and Goto S In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives Antimicrob Agents Chemother 38 1118-1122 1994
19 Tsuji A, Kaneko Y, Yamaguchi K and Goto S Correlation between the in vitro and in vivo effects of fourteen β-lactam compounds in mice with systemic infection Chemotherapy 40 324-332 1994
20 Matsumoto T, Kaku M, Tateda K, Furuya N, Hirakata Y and Yamaguchi K Detection of antibody-coated bacteria in expectorated sputum for diagnosis of lower respiratory infections Microbiol Immunol 38 287-293 1994
21 Tateda K, Ishii Y, Hirakata Y, Matsumoto T, Ohno A and Yamaguchi K Profiles of outer membrane proteins and lipopolysaccharide of Pseudomonas aeruginosa grown in the presence of sub-MICs of macrolide antibiotics and their relation to enhanced serum sensitivity J Antimicrob Chemother 34 931-942 1994
22 Tateda K, Ishii Y, Matsumoto T, Hirakata Y and Yamaguchi K Suppressive effect of clindamycin on development of β-lactam resistance in Enterobacter cloacae ATCC 23355 J Antimicrob Chemother 34 281-286 1994
23 Mizukane R, Hirakata Y, Kaku M, Ishii Y, Furuya N, Ishida K, Koga H, Kohno S and Yamaguchi K Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa Antimicrob Agents Chemother 38 528-533 1994
24 Kobayashi I, Hasegawa M, Miyazaki S, Nishida M and Goto S In vitro and in vivo changes of serotype in Pseudomonas aeruginosa isolates by anti-pseudomonal drugs J Antibiot 47 72-79 1994
25 Iwasaki H, Miyazaki S, Tsuji A, Yamaguchi K and Goto S In vitro and in vivo antibacterial activities of Q-35, a novel fluoroquinolone Chemotherapy 41 100-112 1995
26 Ishii Y, Ohno A, Taguchi H, Imajo S, Ishiguro M and Matsuzawa H Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A β-lactamase isolated from Escherichia coli Antimicrob Agents Chemother 39 2269-2275 1995
27 Asahi Y, Miyazaki S and Yamaguchi K In vitro and in vivo antibacterial activities of BO-2727, a new carbapenem Antimicrob Agents Chemother 39 1030-1037 1995
28 Kodaka H, Ishikawa M, Iwata M, Kashitani F, Mizuochi S and Yamaguchi K Evaluation of new medium with chromogenic substrates for members of the family Enterobacteriaceae in urine samples J Clin Microbiol 33 199-201 1995
29 Ohno A, Isii Y, Tateda K, Matsumoto T, Miyazaki S, Yokota S and Yamaguchi K Role of LPS length in clearance rate of bacteria from the bloodstream in mice Microbiology 141 2749-2756 1995
30 Hirakata Y, Furuya N, Tateda K, Matsumoto T and Yamaguchi K The influence of exo-enzyme S and proteases on endogenous Pseudomonas aeruginosa bacteraemia in mice J Med Microbiol 43 258-261 1995
31 Ishida Y, Miyazaki S, Yamaguchi K and Goto S In vitro and in vivo activ-ity of DQ-2556, a new cephalosporin Chemotherapy 41 5-13 1995
32 Matsumoto T, Tateda K, Ishii Y, Ohno A, Miyazaki S and Yamaguchi K In vitro and in vivo antibacterial activities of broad spectrum quinolones against clinical bacterial isolates Drugs 49 219-221 1995
33 Miyazaki S, Matsumoto T, Tateda K, Ohno A and Yamaguchi K Role of exotoxin A in inducing severe Pseudomonas aeruginosa infections in mice J Med Microbiol 43 169-175 1995
34 Hirakata Y, Furuya N, Tateda K and Yamaguchi K A protective role for lymphocytes in cyclophosphamide-induced endogenous bacteraemia in mice J Med Microbiol 43 141-147 1995
35 Hirakata Y, Furuya N, Matsumoto T, Tateda K and Yamaguchi K Influence of various immunosuppressive agents on the occurrence of endogenous bacteraemia in mice J Med Microbiol 42 181-185 1995
36 Tsuji M, Ishii Y, Ohno A, Miyazaki S and Yamaguchi K In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin Antimicrob Agents Chemother 39 2544-2551 1995
37 Hirakata Y, Furuya N, Matsumoto T, Tateda K and Yamaguchi K The influence of immunosuppressive agents on the immune system of mice Immunol Infect Dis 5 88-93 1995
38 Tateda K, Takashima K, Miyazaki H, Matsumoto T, Hatori T and Yamaguchi K Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model Antimicrob Agents Chemother 40 1520-1525 1996
39 Tateda K, Ishii Y, Matsumoto T, Furuya N, Nagashima M, Matsunaga T, Ohno A, Miyazaki S and Yamaguchi K Direct evidence for antipseudomonal activity of macrolides:exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin and azithromycin Antimicrob Agents Chemother 40 2271-2275 1996
40 Tateda K, Matsumoto T, Miyazaki S and Yamaguchi K Lipopolysaccharide-induced lethality and cytokine production in aged mice Infect Immun 64 769-774 1996
41 Hirakata Y, Furuya N, Matsumoto T, Tateda K and Yamaguchi K Experimental endogenous septicaemia caused by Klebsiella pneumoniae and Escherichia coli in mice J Med Microbiol 44 211-214 1996
42 Takashima K, Tateda K, Matsumoto T, Ito T, Iizawa Y, Nakao M and Yamaguchi K Establishment of a model of penicillin-resistant Streptococcus pneumoniae pneumonia in healthy CBA/J mice J Med Microbiol 45 319-322 1996
43 Hirakata Y, Furuya N, Iwata M, Kashitani F, Ishikawa M, Yumoto S, Yasui K, Endoh H, Marui A, Kaku M, Tateda K and Yamaguchi K Assessment of clinical significance of positive blood cultures of relatively low-virulence isolates J Med Microbiol 44 195-198 1996
44 Miyazaki S, Matsumoto T, Tateda K and Yamaguchi K In vitro and in vivo evaluation of DU6859a, a new fluoroquinolone, among injectable antibacterials tested against clinical isolates J Infect Chemother 2 148-155 1996
45 Miyazaki S, Nunoya T, Matsumoto T, Tateda K and Yamaguchi K New murine model of bronchopneumonia due to cell-bound Haemophilus influenzae J Infect Dis 175 205-209 1997
46 Matsumoto T, Tateda K, Miyazaki S, Furuya N, Ohno A, Ishii Y, Hirakata Y and Yamaguchi K Immunomodulating effect of fosfomycin on gut-derived sepsis caused by Pseudomonas aeruginosa in mice Antimicrob Agents Chemother 41 308-313 1997
47 Irie Y, Tateda K, Matsumoto T, Miyazaki S and Yamaguchi K Antibiotic MICs and short time-killing against Helicobacter pylori:therapeutic potential of kanamycin J Antimicrob Chemother 40 235-240 1997
48 Matsumoto T, Tateda K, Miyazaki S, Furuya N, Ohno A, Ishii Y, Hirakata Y and Yamaguchi K Adverse effects of tumour necrosis factor in cyclophosphamide-treated mice subjected to gutderived Pseudomonas aeruginosa sepsis Cytokine 9 763-769 1997
49 Miyazaki S, Domon H, Tateda K, Ohno A, Ishii Y, Matsumoto T, Furuya N and Yamaguchi K In vitro and in vivo antibacterial activities of CS-940, a new fluoroquinolone, against isolates from patients with respiratory infections Antimicrob Agents Chemother 41 2582-2585 1997
50 Takashima K, Tateda K, Matsumoto T, Iizawa Y, Nakao M and Yamaguchi K Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice Infect Immun 65 257-260 1997
51 Ohno A, Marui A, Castro ES, Reyes AA, Elio-Calvo D, Kasitani F, Ishii Y and Yamaguchi K Enteropathogenic bacteria in the La Paz river of Bolivia American J. Trop Med Hyg 57 438-444 1997
52 Matsumoto T, Tateda K, Furuya N, Miyazaki S, Ohno A, Ishii Y, Hirakata Y and Yamaguchi K Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice J Med Microbiol 47 303-308 1998
53 Matsumoto T, Tateda K, Miyazaki S, Furuya N, Ohno A, Ishii Y, Hirakata Y and Yamaguchi K Effect of immunisation with Pseudomonas aeruginosa on gut-derived sepsis in mice J Med Microbiol 47 295-301 1998
54 Matsumoto T, Tateda K, Miyazaki S, Furuya N, Ohno A, Ishii Y, Hirakata Y and Yamaguchi K Effect of interleukin-10 on gut-derived sepsis caused by Pseudomonas aeruginosa in mice Antimicrob Agents Chemother 42 2853-2857 1998
55 Yoshizumi S, Domon H, Miyazaki S and Yamaguchi K In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens Antimicrob Agents Chemother 42 785-788 1998
56 Homma S, Takimoto E, Kawabata M, Kishi K, Tsuboi E, Narui K, Nakatani T, Inagawa Y, Tateda K and Yamaguchi K The first recognized patients with Legionella pneumophila serogroup 9 pneumonia in Japan J Infect Chemother 4 214-218 1998
57 Ma L, Ishii Y, Ishiguro M, Matsuzawa H and Yamaguchi K Cloning and sequencing of the gene encoding Toho-2, a class A β-lactamase preferentially inhibited by tazobactam Antimicrob Agents Chemother 42 1181-1186 1998
58 Hirakata Y, Izumikawa K, Yamaguchi T, Igimi S, Furuya N, Maesaki S, Tomono K, Yamada Y, Kohno S, Yamaguchi K and Kamihira S Adherence to and penetration of human intestinal Caco-2 epithelial cell monolayers by Pseudomonas aeruginosa Infect Immun 66 1748-1751 1998
59 Yamaguchi K, Domon H, Miyazaki S, Tateda K, Ohno A, Ishii Y, Matsumoto T and Furuya N In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem Antimicrob Agents Chemother 42 555-563 1998
60 Arakawa S, Matsui T, Kamidono S, Kawada Y, Kumon H, Hirai K, Hirose T, Matsumoto T, Yamaguchi K, Yoshida T, Watanabe K, Ueno K, Saito A and Teranishi T Derivation of a calculation formula for breakpoints of antimicrobial agents in urinary tract infections J Infect Chemother 4 97-106 1998
61 Miyazaki S, Tateda K, Ohno A, Ishii Y, Matsumoto T, Furuya N and Yamaguchi K In vitro and in vivo antibacterial activities of quinupristin-dalfopristin, a novel injectable streptogramin, against gram-positive cocci and gram-negative respiratory tract pathogens J Infect Chemother 4 64-70 1998
62 Tamura S, Miyazaki S, Tateda K, Ohno A, Ishii Y, Matsumoto T, Furuya N and Yamaguchi K In vivo antibacterial activities of sanfetrinem cilexetil, a new oral tricyclic antibiotic Antimicrob Agents Chemother 42 1858-1861 1998
63 Tsuji M, Ishii Y, Ohno A, Miyazaki S and Yamaguchi K In vitro and in vivo antibacterial activities of S-4661, a new carbapenem Antimicrob Agents Chemother 42 94-99 1998
64 Tateda K, Matsumoto T and Yamaguchi K Acute induction of interleukin-6 and biphasic changes of serum complement C3 by carrageenan in mice Mediators Inflam 7 221-223 1998
65 Tateda K, Matsumoto T, Ishii Y, Furuya N, Ohno A, Miyazaki S and Yamaguchi K Serum cytokines in patients with Legionella pneumonia:Relative predominance of Th1-type cytokines Clin Diagn Lab Immunol 5 401-403 1998
66 Tateda K, Murakami H, Ishii Y, Furuya N, Matsumoto T and Yamaguchi K Evaluation of clinical usefulness of the microplate agglutination test for serological diagnosis of Legionella pneumonia J Med Microbiol 47 325-328 1998
67 Tomizawa H, Tateda K, Miyazaki S and Yamaguchi K Antibacterial activity of AM-1155 against penicillin-resistant Streptococcus pneumoniae J Antimicrob Chemother 41 103-106 1998
68 Ishida Y, Kurosaka Y, Murakami Y, Otani T and Yamaguchi K Therapeutic effect of oral Levofloxacin, Ciprofloxacin and Ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar Chemotherapy 45 183-191 1999
69 Miyazaki S, Matsumoto T, Furuya N, Tateda K and Yamaguchi K The pathogenic role of fimbriae of Haemophilus influenzae type b in murine bacteraemia and meningitis J Med Microbiol 48 383-388 1999
70 Matsumoto T, Furuya N, Tateda K, Miyazaki S, Ohno A, Ishii Y, Hirakata Y and Yamaguchi K Effect of passive immunotherapy on murine gutderived sepsis caused by Pseudomonas aeruginosa J Med Microbiol 48 765-770 1999
71 Kimura K, Miyazaki S, Tateda K, Matsumoto T, Tsujimoto S and Yamaguchi K Factors affecting the course and severity of transnasally induced Staphylococcus aureus pneumonia in mice J Med Microbiol 48 1005-1010 1999
72 Tateda K, Matsumoto T, Miyazaki S and Yamaguchi K Efficacy of β-lactam antibiotics combined with gentamicin against penicillin-resistant pneumococcal pneumonia in CBA/J mice J Antimicrob Chemother 43 367-371 1999
73 Matsumoto T, Tateda K, Miyazaki S, Furuya N, Ohno A, Ishii Y, Hirakata Y and Yamaguchi K Paradoxical synergistic effects of tumour necrosis factor and interleukin 1 in murine gutderived sepsis with Pseudomonas aeruginosa Cytokine 11 366-372 1999
74 Miyazaki S, Ishii Y, Ohno A, Furuya N, Matsumoto T, Tateda K and Yamaguchi K In-vitro activities of 11 antibiotics against vancomycin-resistant enterococci isolated in Japan J Antimicrob Chemother 44 415-416 1999
75 Ibuka A, Taguchi A, Ishiguro M, Fushinobu S, Ishii Y, Kamitori S, Okuyama K, Yamaguchi K, Konno M and Matsuzawa H Crystal structure of the E166A mutant of extended-spectrum β-lactamase Toho-1 at 1.8 A resolution J Mol Biol 285 2079-2087 1999
76 Higashi Y, Watanabe A, Matsumoto Y, Watanabe Y and Ohno A Role of inhibition of penicillin binding proteins and cell wall cross-linking by β-lactam antibiotics in low- and high-level methicillin resistance of Staphylococcus aureus Chemotherapy 45 37-47 1999
77 Matsumoto T, Tateda K, Miyazaki S, Furuya N, Ohno A, Ishii Y, Hirakata Y and Yamaguchi K Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in mice Clin Diagn Lab Immunol 6 537-541 1999
78 Matsumoto T, Tateda K, Miyazaki S, Furuya N, Ohno A, Ishii Y, Hirakata Y and Yamaguchi K Fosfomycin alters lipopolysaccharide-induced inflammatory cytokine production in mice Antimicrob Agents Chemother 43 697-698 1999
79 Yamaguchi K, Mathai D, Biedenbach DJ, Lewis MT, Gales AC and Jones RN Evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan Diagn Microbiol Infect Dis 34 123-134 1999
80 Saito A, Inamatsu T, Okada J, Oguri T, Kanno H, Kusano N, Kumon H, Yamaguchi K, Watanabe A and Watanabe K Clinical breakpoints in pulmonary infections and sepsis: new antimicrobial agents and supplemental information for some agents already released J Infect Chemother 5 223-226 1999
81 Hirakata Y, Ishii Y, Nakano M, Matsuda J, Ozaki Y, Mochida C, Iori F, Ma L, Izumikawa K, Yamaguchi T, Miyazaki Y, Maesaki S, Tomono K, Yamada Y, Yamaguchi K, Kamihira S and Kohno S Two sporadic cases of infections due to Klebsiella pneumoniae resistant to expanded-spectrum cephalosporins in Japan J Infect Chemother 5 91-96 1999